ArticleInternational journal of clinical and experimental pathology2018
miR-483-3p promotes proliferation and migration of neuroblastoma cells by targeting PUMA.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- MicroRNAs in Esophageal Cancer: Implications for Diagnosis, Progression, Prognosis and Chemoresistance.International journal of molecular sciences · 2026Review
- Microrna Expression inMicroRNA (Shariqah, United Arab Emirates) · 2026Article
- Integrative Regulatory Networks of MicroRNA-483: Unveiling Its Systematic Role in Human Diseases and Clinical Implications.Biomolecules · 2025Review
- The multifaceted role of PUMA in cell death pathways: its therapeutic potential across cancer types.Cell communication and signaling : CCS · 2025Review
- A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells.Cell death & disease · 2025Article
- Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.Medical oncology (Northwood, London, England) · 2024Article
- MiR-483-3p improves learning and memory abilities via XPO1 in Alzheimer's disease.Brain and behavior · 2022Article
- CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p.Cell cycle (Georgetown, Tex.) · 2022Article
- MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the most common extra-cranial solid tumor in infants and children and accounts for about 15% of deaths from childhood cancers. MicroRNAs (miRNAs) have been shown to play an important role in several cellular processes, such as cell proliferation, apoptosis, invasion, metastasis and angiogenesis, and therefore have been implicated in cancer progression. miR-483-3p is associated with neuroblastoma and is found to function as an 'onco-miR' in some malignancies. However, its role in neuroblastoma remains poorly understood. In this study, we confirmed that miR-483-3p is overexpressed in neuroblastoma tissue when compared with normal tissue and miR-483-3p expression is also associated with tumor stage. Overexpression of miR-483-3p substantially enhanced cell proliferation, migration, and invasion of neuroblastoma cells. miR-483-3p also promoted tumor growth of neuroblastoma
Indexed as
Identifiers
31938135PMC6958035W3027166895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.